Intellipharmaceutics International Inc. (IPCI)

[fred198484]

Just so everyone is prepared for the ad com meeting, a few days before the FDA will release a dossier on the drug which will include questions for the panel to address. Some investors in the past have mistaken these questions as criticisms the FDA has of a drug. BAsically, it is just the issues they want the panel to discuss to get their feedback on them and may not be suggestive that the FDA is unhappy with the drug. I once saw a drug stock fall by 50% when the FDA's dossier was released simply because the market mistakenly read that the FDA was critical of the drug and approval was not going to happen. The Ad Com panel then voted 17-0 in favor of approving the drug and the stock quickly gained back all it had lost and then some. So, if the way the FDA has worded things in its dossier first gets you worried, take a minute to consider that they are trying to stir up the discussion with the Ad Com panelists and are not necessarily being critical of the drugs prospects for approval.